Clinical nutrition (Edinburgh, Scotland) · 2025
Effects of 5:2 intermittent fasting meal replacement on body composition and abdominal fat distribution in overweight and obese adults with early type 2 diabetes.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Dongni, Zou Mingzhu, Cheng Bo, Yang Peng, Huang Dongni, Pan Qi, Guo Lixin
Аннотация
BACKGROUND AND AIMS: The 5:2 intermittent fasting meal replacement (5:2 MR) improved glycemic control and weight loss in adults with type 2 diabetes mellitus (T2DM).
OBJECTIVE: This analysis further investigated the exploratory outcomes related to body composition and abdominal fat distribution.
METHODS: This was a single-center analysis of a randomized, active-controlled trial (EARLY), which enrolled overweight and obese patients with early T2DM. A total of 85 participants were randomly assigned to receive metformin (n = 28), empagliflozin (n = 28), or 5:2 MR (n = 29) for 16 weeks. Body composition was assessed using InBody device, and the energy spectrum CT was used to measure abdominal fat distribution. Spearman's correlation coefficient was used to evaluate the associations between change in body mass index (BMI) and change in the exploratory outcomes.
RESULTS: Compared with the metformin and empagliflozin groups, the 5:2 MR group showed the most significant reductions in BMI (least-squares mean, -3.41 kg/m2 [standard error, 0.31], P < 0.001), waist circumference (-8.83 cm [1.07], P < 0.001), waist-to-hip ratio (WHR) (-0.04 [0.01], P < 0.05), waist-to-height ratio (WHtR) (-0.05 [0.01], P < 0.001), body fat percentage (BF%) (-4.84 % [0.66], P < 0.05), abdominal cross-sectional area (ACSA) (-66.05 cm2 [9.46], P < 0.01), subcutaneous fat area (-58.27 cm2 [5.99], P < 0.001), and an increase in the liver-to-spleen (L/S) ratio) (0.43 [0.04], P < 0.01). In the 5:2 MR group, changes in BMI exhibited linear associations and significant positive correlations with changes in WHR (r = 0.411, P = 0.030), WHtR (r = 0.635, P < 0.001), BF% (r = 0.528, P = 0.020) and ACSA (r = 0.562, P = 0.003).
CONCLUSION: The 5:2 MR regimen may be more effective than metformin and empagliflozin in improving body composition and abdominal fat distribution in early T2DM, and is proposed as a therapeutic option.
OBJECTIVE: This analysis further investigated the exploratory outcomes related to body composition and abdominal fat distribution.
METHODS: This was a single-center analysis of a randomized, active-controlled trial (EARLY), which enrolled overweight and obese patients with early T2DM. A total of 85 participants were randomly assigned to receive metformin (n = 28), empagliflozin (n = 28), or 5:2 MR (n = 29) for 16 weeks. Body composition was assessed using InBody device, and the energy spectrum CT was used to measure abdominal fat distribution. Spearman's correlation coefficient was used to evaluate the associations between change in body mass index (BMI) and change in the exploratory outcomes.
RESULTS: Compared with the metformin and empagliflozin groups, the 5:2 MR group showed the most significant reductions in BMI (least-squares mean, -3.41 kg/m2 [standard error, 0.31], P < 0.001), waist circumference (-8.83 cm [1.07], P < 0.001), waist-to-hip ratio (WHR) (-0.04 [0.01], P < 0.05), waist-to-height ratio (WHtR) (-0.05 [0.01], P < 0.001), body fat percentage (BF%) (-4.84 % [0.66], P < 0.05), abdominal cross-sectional area (ACSA) (-66.05 cm2 [9.46], P < 0.01), subcutaneous fat area (-58.27 cm2 [5.99], P < 0.001), and an increase in the liver-to-spleen (L/S) ratio) (0.43 [0.04], P < 0.01). In the 5:2 MR group, changes in BMI exhibited linear associations and significant positive correlations with changes in WHR (r = 0.411, P = 0.030), WHtR (r = 0.635, P < 0.001), BF% (r = 0.528, P = 0.020) and ACSA (r = 0.562, P = 0.003).
CONCLUSION: The 5:2 MR regimen may be more effective than metformin and empagliflozin in improving body composition and abdominal fat distribution in early T2DM, and is proposed as a therapeutic option.